Cardiff Oncology Q4 2023 GAAP EPS $(0.210) Beats $(0.280) Estimate, Sales $156.000K Beat $37.500K Estimate
Portfolio Pulse from Benzinga Newsdesk
Cardiff Oncology (NASDAQ:CRDF) reported Q4 2023 earnings with a GAAP EPS of $(0.210), surpassing the $(0.280) estimate. Sales reached $156,000, exceeding the $37,500 estimate by 316% and marking a 21.88% increase from the previous year.
February 29, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardiff Oncology reported a better-than-expected Q4 2023 with EPS of $(0.210) and sales of $156,000, significantly beating estimates.
Cardiff Oncology's Q4 2023 performance exceeded analyst expectations in both EPS and sales, indicating a strong financial position and potential growth. The significant beat on sales estimates, coupled with a better-than-expected EPS, suggests operational efficiency and could lead to positive investor sentiment in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100